Study Results – ACTG Network

REPRIEVE TRIAL Cardiovascular Disease Risk and Prevention in Inflammation: The REPRIEVE Trial in HIV

January 11, 2023 Alexis Sexton Study Results

To see study results from the REPRIEVE trial click here.

Read more
A5360 (MINMON): A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to Populations Living with HCV Who Are HCV Treatment Naïve with Evidence of Active HCV Infection

October 20, 2021 Alexis Sexton Study Results

To see study results from A5360 click here.

Read more
A5305: Phase II Study of Maraviroc (MVC)-Containing Regimens for HIV PrEPin MSM, Transgender Women and Cisgender Women

October 20, 2021 Alexis Sexton Study Results

To see study results from A5305 click here.

Read more
A5349: Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis

October 20, 2021 Alexis Sexton Study Results

To see study results from A5349 click here.

Read more
A5336: A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults

October 20, 2021 Alexis Sexton Study Results

To see study results from A5336 click here.

Read more
A5333s: Mechanistic Sub-study of A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

October 20, 2021 Alexis Sexton Study Results

To see results of A5333s click here.

Read more